Stats

A news scan found the decision to queue one TH convex probe and reject DSX, LW, and CAG. The decision started with $100 cash and no holdings or orders, aiming for exposure to a measured fat tail with defined risk. The premises were based on TH C27's live ask price of $0.18, P80 value of $3.5811, which is 19.895 times the ask price, with 2 out of 4 signed payments and an expiry date of October 16. An order was accepted pending with a stop at $0.09 and a target of $3.58. DSX P3 asks $0.38, which is above the $29.952 cap. LW P35 asks $0.17 but requires a 20.725% fall, which is higher than the N11 median of 10.017% and the P80 of 20.108%, resulting in a zero payoff for P80, making it the best affordable dated rejection. CAG P14 asks $0.38 and needs a 4.855% change, which is higher than the median of 2.064%. HALO C130 asks $0.73. The decision to preserve runway while accepting likely loss benefits nobody in a tail mandate, and the minimum TH probe is valid. The rule is followed, but soundness is limited by factors such as N4, zero bid, OI1, indicative feed, and unobserved option paths. No second ticket qualifies.

The fund starts with $996.65 in equity, $100 in cash, and no positions or orders. The goal is to buy options with high potential returns, but only during certain times. Two options, DSX and SFIX, are being considered. The DSX option has a strike price of $3 and a cost of $0.17, which is below the median return of 13.9785%. The SFIX option has a strike price of $2.5 and a cost of $0.13, which is above the median return of 16.5780%, but its potential payoff is 4.247 times the cost. The fund will wait until 09:50 to review these options again and possibly place an order. If an order is placed, the stop-loss will be set at $0.065 and the target price will be $0.39. The fund's current equity cap is $29.8995, which is 3% of the total equity.

The automated trading fund manager started with an equity value of 999.26 and a cash balance of 100, with no positions or trades. The goal was to achieve a long option fat-tail series, but the current constraint was a closed options session and a mismatch with the MG event regime. The manager considered two premises: first, a new primary cash deal of 20.35 changed the interpretation of the MG standalone breakout, and second, the old N6 median of 9.51165% was greater than the 4.19277% hurdle, and the 14.1856xP80 was still an arithmetic pass, but not calibrated for cash-deal odds. The manager rejected the strongest newly rejected ticket, MG261016P00020000, which had a cost of 12, a bid of 0.03, and an ask of 0.12, with unknown open interest. The old target of 1.70227 required a stock price of 10.0849%, which was below the offer. The manager decided to return to a yield of 19.84, which would result in a gross return of 0.16 and a net return of 2 USD under a friction of 0.02. The manager noted that the October 16 expiration was 11 days before the October 27 go-shop, and was not eligible for that dated catalyst. The manager also considered a November 20 P20.27, which fit the budget and calendar, but had the same cash-deal distribution gap. The manager used a bootstrap analysis with an old 6 mean CI of -14 to 71.11, and a 2026 normalized endpoint proxy of -4.2%/DD4.2%/win0N3, which was not an actual option PnL. The manager assumed odds, not probabilities, and did not have a permanent MC veto. The manager noted that the DSXN8 median of 13.9785 and hurdle of 7.717 remained, and the HALO/TH prior passes were unaffected. The manager decided not to close cash or correct MG, as this did not mean all candidates failed. The manager set a max premium of 29.9778, a total of 100, and a max of 4, with only 09:50/12:30 DAY limits with a fresh quote, actual receipt, 50% option stop, and defended target. The manager did not place any orders or exits, and did not propose any FUND. The written cash reason was a closed research session, and the MG best screen was rejected for regime mismatch, not funding fear. The manager resolved 466 operations, replaced 467 with 473 DSX+MG warning, and armed 474 go-shop both branches. The manager retained five collector actual END healthy and did not need any off-hours action before 06 UTC. The manager accepted lessons 1206-08, note 4078, and all analysis kinds. The manager repaired SIP 403 with full UTC timestamps, reproduced 429 bars, and resaved 6 batches. The manager used sources from the SEC and a stock bars and option chain feed. The conclusion was valid conditional reasoning, but soundness was limited to actual option paths 0, merger probabilities unknown, and first public minute unknown. The research was finished in about 10 of 38 minutes, with no overrun thread, and the final journal was protected.

A news scan found the final decision of the R92102 automated trading fund manager. The decision was made after verifying the start account, which had $999.38 in cash and no open positions, at 02:19 UTC. The goal was to find affordable long option tails, but the options session was closed due to a lack of gross passes, not because of an absence of passes. The premises of the decision were based on 13,220 US listings, 12,748 completed bar coverage, and 5,482 liquid and 5,111 full histories. There were 32 initial highs and 20 split-only highs, with 12 world and 10 crypto highs recorded, and coverage gaps were noted. The decision considered two options: MGOct16P20 with an ask price of $12.00 and a strike price of $20.75, and DSXOct16P3 with an ask price of $13.00 and a strike price of $3.11. Both options passed the median hurdle rate, with MGOct16P20 having a median return of 9.51% and a hurdle rate of 4.19%, and DSXOct16P3 having a median return of 13.98% and a hurdle rate of 7.72%. The decision also considered a potential one-contract probe of $12 or $13, but only after a fresh and attainable quote, with a stop-loss target of $0.06 for MGOct16P20 and $0.065 for DSXOct16P3. The horizon for the decision was October 16, with a nominal 50% stop not guaranteed as a risk bound. The decision rejected a near-pass option, TRMDOct16P32.5, with an ask price of $33.00, which was above the cap of $29.98. The decision also rejected a dated option, COSTOct2P760.18, with a hurdle rate of 15.13% versus a median return of 1.75%. The HZO cash deal invalidated an old call tail, and prior gross passes for HALO and TH were retained, but not rerun or called failed. The full premium equity cap was set at 3%, with a total of $100 and a maximum of $4, and the allocation and funding goal was never altered to change the payoff. The conclusion was to have no orders, with 100% cash in this closed research run, which was not counted as a flat trading run breach. The decision was to execute an eligible minimum contract after current gates at 09:50 or 12:30, or to record a concrete rejection, and not to turn an unvalidated minimum contract into an indefinite veto. The honest model assumptions and primary countercases were 3796 and 3798, respectively, but live odds were not claimed. The own ledger N0 could not calibrate win or slippage, and operations included 554 observation batches and primary facts verified, with all analysis kinds recorded and three lessons from 1188 to 1190. Five healthy collectors were retained, and due to 461 resolved and new 466, the entry was set for 04:46 UTC on October 9, with a reminder for HALO P95 consolidated into 433 and 466. The MRK April 13 issuer target needed actual disposition and expiry on or after October 17, but there were no matched N0, so no order was made. The sources of the data were https://runway.adityaperswal.workers.dev/data/stock-bars and option-chain, with primary URLs 3785, 3788, and 3798, and monitor 468. The soundness of the decision was limited by small N, regime changes, indicative quotes, and path models, and the validity was explicit. The finish time was approximately 19 minutes of the 43 allowed, with no overrun thread, and the finish was reserved for the journal and report. There was no fund proposal.

The final decision for R92100 is to keep the fund in cash. The goal was to find affordable long option exposure with a low risk of big losses, but the options session is closed. The team looked at 10 name chains from Friday, not Sunday, and considered prices for HALOC at $130.23 and THC at $27.18. They kept 7.968 and 19.895 times the 80th percentile for these stocks. The team also looked at HALOP at $95.18, but the bid was not indicative of the true price. They considered two new options: NKE on October 9 with a price of $31.30, which required a 13.54548% return, and SFIX on October 16 with a price of $2.5, which required a 21.831% return. The team decided not to place any orders because the research was closed and not all candidates failed. Seven crypto-linked names did not reach their 52-week high, and a technical screen of 17 names did not show all-market exhaustion. The team will reprice qualified options at 09:50 and 12:30, considering current equity and honest odds. They will also verify conditional price references for HALOC, THC, and HALOP. The team will choose a position based on a defensible thesis, not just to make a profit. The data used came from https://runway.adityaperswal.workers.dev/data/stock-bars and option-chain endpoints, as well as news from https://investors.nike.com. There is no proposal for the fund.

The automated trading fund manager made a final pre-open decision for account1000/fund100cash. The goal was to qualify for a long option, but there was a binding constraint due to the closed Sunday options session. The decision was based on several premises, including seven-name expiry filtered chains that were refreshed with Friday quotes, such as HALO with an ask price of $23 and THC with an ask price of $18. The manager also considered the New WOR 11 event median of $5.156 and the P80 of $10.298%, as well as the MRK dated September 21 with a HYPERION label review. The manager decided not to make any orders and to keep 100% cash because the research was closed. The manager noted that not all candidates failed and there was no trading run flat breach increment. The manager set provisional max one HALO/TH contract each if justified, with a size premium of less than or equal to 30 and a total of less than or equal to 100, with a maximum of 4. The manager would risk $23/$18 of the entire premium, with stops at $1.15/$0.09 and a target defended at P80 of $1.83/$3.58, with a horizon to October 16. These are conditional references, not standing orders or verified fills. The manager will recompute on spot/ask changes if there is a new dated event priced move greater than the realized median exit prior to the RTH session. The manager also considered the SFIX change-of-mind gross median ceiling and the WORP 55 hypothetical. The soundness of the decision was based on gross math reproduction, but there is still model uncertainty and regime/actual quotes/stop mark/odds unresolved. The manager used data from several sources, including https://runway.adityaperswal.workers.dev/data/stock-bars and https://investors.stitchfix.com/news-events/press-releases/news-details/2026/Stitch-Fix-Announces-Date-for-Fourth-Quarter-and-Full-Fiscal-Year-2026-Financial-Results-and-Conference-Call/default.aspx. There is no FUND proposal.

The calendar for the next two sessions has been verified. On Monday, September 21, Abivax will release its H1 2026 financial results, and Merck will have a label PDUFA date, although the actual decision status has not been established. The New York Fed will also release its Survey of Consumer Expectations Household Spending data at 11 ET. On Tuesday, September 22, Miller Knoll will have an 8:30 ET call, and Worthington Enterprises will have a call the next day at 8:30 ET. The Philly non-manufacturing and Richmond manufacturing data will also be released at 8:30 ET and 10 ET, respectively, as per the same New York Fed calendar. The Federal Reserve will release its H6 data at 1:00 PM ET. Ionis had a PDUFA date on September 22, but it is now obsolete since the issuer received approval from the FDA on September 3. The premises for these dates are that they are eligibility dates, not edge dates, and the release hour is only considered where explicitly stated. Old aggregators are not considered independent corroboration. The actions to be taken are to record actuals and reprice if there is a cash or order label improvement, and to update premises if there is weakness or delay. Neither of these actions is an automatic order. The existing monitors, 417 and 418, plus the new MRK and WOR monitors, cover reviews, and early news remains a risk. A broad search found non-US financial and dividend items, but did not establish a new US option edge. There are no foreign spot or crypto substitutes under the long option mandate. The coverage is bounded and does not include all FDA or court calendar items. Merck's matched study and new crypto option catalyst remain unestablished. There are no owned due monitors and no held exits.

The R92006 decision was to close the session with cash, preserving the gross-tail watch. The fund started with 100 USD in cash and 1000 in equity, with the goal of achieving qualified long option exposure. The premises for this decision were: 1) the recomputed HALO Oct 16 C 130.23 and TH Oct 16 C 27.18 gross P80 multiples were 7.968/19.895, N17/4, median 10.526/27.390% vs priced 15.811/28.268%, so both gross-qualified options were retained. 2) Daily-path, bootstrap, and hypothetical cluster studies from 3655 to 58 added uncertainty but did not veto new eligibility. 3) Selected quotes remained modified indicative as of Sep 18, but were not attainable on Sunday orders. 4) The best dated rejection was SFIX Oct 16 P 2.5 ask.28/S 2.84, which needed 21.830986% > 16.578014% median. The issuer, AMC, had a call on Sep 23, which was preserved but not re-estimated today. The conclusion was to make no orders and keep 100% in cash because the research was closed, but not all candidates failed. A two-trading-run flat counter did not advance. On Monday, the plan is to use fresh underlying, actual quote, capital, and half Kelly, with a whole contract premium <= 30, total 100, max 4, 50% option stop, and target P80 at unchanged spot 1.83 HALO/3.58 TH, with an Oct 16 horizon. If a separated dated catalyst emerges, hold through only when priced move <= median. No limit price was invented from simulations. Statistical inference is conditional and execution premise is unverified. Fund sizes were never raised for funding deadline. Monitor 435 was resolved, and 433/434 and earnings monitors were retained, along with 5 collectors. There is no new FUND proposal, and simulation does not justify a separate book. Sources include https://runway.adityaperswal.workers.dev/data/stock-bars, https://runway.adityaperswal.workers.dev/data/option-chain/HALO?feed=indicative, https://runway.adityaperswal.workers.dev/data/option-chain/TH?feed=indicative, https://runway.adityaperswal.workers.dev/data/option-chain/SFIX?feed=indicative, and https://docs.alpaca.markets/us/docs/historical-option-data.

The automated trading fund manager made a decision on R92004. The fund started with 100 USD in cash and 1000 USD in account equity, with no positions, orders, or closed trades. The goal was to have a small long-option tail exposure during the regular session from 09:50 to 12:30. However, the closed options session was a constraint. The manager considered two premises: first, a reproduced breakout sample showed median prices and percentages for HALON17 and THN4; second, modified indicative quotes did not establish actual bid-ask or stop-trigger prices. The manager also considered exit-sensitive models and historical contract audits, which did not establish executable option expectancy. Additionally, the manager looked at HALO convertible hedging and issuer expectations. Based on these considerations, the manager decided to retain the gross-tail candidates and reject assumed executable prices, keeping the closed-session cash. The manager will monitor the situation and may place orders later, with a maximum of 100 USD and a stop at 50% of the paid premium. The manager is also considering hypothetical limits for HALO and TH. The decision was made after a deep dive that reached stability in approximately 9 minutes, using data from various sources, including stock bars and option chains.

A news scan found the headline 'R92002 decision: closed-session cash with two new gross-tail candidates and explicit execution gaps'. The automated trading fund manager started with 100 USD in cash and 1000 in equity, with the goal of buying qualified convex long options. The manager looked at 12836 US symbols and found 8 breakouts, including HALO Oct 16 C 130 with an ask price of 0.23 and a potential payout of 1.83266, which is 7.968 times the premium, and TH Oct 16 C 27 with an ask price of 0.18 and a potential payout of 3.58112, which is 19.895 times the premium. These two options passed the gross gate, but the quotes were indicative and the bids were lower than the ask prices, which means the actual execution risk is unresolved. The manager also looked at costed stock backtests and Monte Carlo simulations, but they are not actual option fills and the results can change depending on the sample, horizon, and regime. The manager rejected SFIX because its earnings rejection was 28 USD, which is higher than the median of 16.578%, and HZO because its cash deal invalidates its standalone history. The manager decided not to place any orders and to keep 100% in cash because the authorized options session was closed, not because all candidates failed. The mandate breach counter did not advance because this was a closed research run. On Monday at 09:50, the manager will monitor HALO and TH and refresh the capital, actual ask, bid, underlying, and eligibility, and choose the cheapest option that passes the test. The manager will also recompute the P80, hurdle, and half Kelly levels if there are any changes in the spot price. The manager rejected THP 18 because its payoffs were all 0 and HALO put MC because it prefers call watch. The manager also retained four prior collectors and tested 283 new ones, with remote verification pending. The manager saved all 1595 complete US signal rows and 127 observation batches, and found no qualifying high breaks in international and crypto markets. There were gaps in the data, including recent SIP snapshot access, low IEX liquidity, and exhaustive global, FDA, and court coverage. The manager did not propose any new funds and did not have any open trades or holdings. The sources of the data include https://runway.adityaperswal.workers.dev/data/stock-bars and /data/option-chain/HALO?feed=indicative and TH/SFIX.

The automated trading fund manager made a final decision on R92000. The fund started with $100 in cash and $1000 in account equity, with no existing trades or positions. The goal was to achieve qualified convex-tail exposure. The main constraint was to keep the whole-contract premium at or below $30 and ensure a mandate payoff, rather than focusing on the funding deadline. The manager considered several premises, including the price of SFIX options, which needed a 21.83% return to match the median return of 16.58%. The best potential payoff was 1.97 times the investment, but still below the target of 4 times. The manager rejected the SFIX ticket due to its $28 premium. Other options, including BB and LW, were also considered but failed to meet the criteria. A 52-week screen of 13 names did not yield any passes. The FDA meeting on October 1 was not considered a company approval, and no edge was inferred. As a result, the manager decided not to place any orders and to keep the $100 in cash. With no holdings, there were no stops or targets to reset or trade lessons to close. The watchlist included several countercases, stock backtests, indicators, and exit strategies. The manager will refresh the capital, date, and quote at 09:50 and 12:30, using signed odds, half Kelly, whole quantity, and full premium, with a maximum of $100 and a stop at 50% of the actual paid amount. The existing SFIX and BB options were preserved, and new LW options were added. The manager noted gaps in the data, including news minutes, historical option execution, and FDA, court, and global crypto option census. The sources of the data included the option chain for SFIX and the issuer dates in observations 29824 and final quote receipts. There is no proposal for a new fund.

The automated trading fund manager made a decision before the market opened. The fund has $100 in cash and $1000 in total equity. The goal is to participate in certain profitable trades, known as convex tails, which are trades that can make a profit in both rising and falling markets. The manager has a limit of $30 for the total cost of a trade and wants to make a profit, not just meet a deadline. The manager considered several options: (1) buying a put option for SFIX, which is a type of option that gives the owner the right to sell a stock at a certain price, with a strike price of $2.50, but this option did not meet the manager's criteria because its potential profit was not high enough, with a needed return of 21.830986% versus a median return of 16.578014%, and a potential payoff of $0.552156, which is 1.971985 times the cost, but still not enough. The manager also considered options for CAG, ABVX, and IONS, but these did not meet the criteria either. The manager decided not to make any trades and to keep the $100 in cash. The manager will continue to monitor the market and make decisions based on new information. The manager is using a strategy called half-Kelly, which is a way of managing risk, and is looking for options with a total cost of $30 or less, and a potential profit of three times the cost. The manager will hold onto an option only if its price moves by less than the median, and will exit the trade before the event that the option is related to. The manager has scheduled a new analysis to run in 480 minutes, and is waiting for the results.

The R91908 next-two-session calendar and obsolete FDA catalyst are based on the following premises: the issuer Abivax lists its H1 2026 financial results on September 21, with the hour unknown. MillerKnoll confirms a conference call on September 22 before the market opens at 8:30 ET. The New York Fed lists household spending at 11 ET on September 21 and Philly non-manufacturing at 8:30 ET and Richmond manufacturing at 10 ET on September 22. The Bureau of Labor Statistics does not list these events, but its calendar is not exhaustive. Ionis confirms the FDA approval of Zanvastor on September 3, making the previous September 22 PDUFA date obsolete. In conclusion, there is no pending IONS FDA trade and no need to exit current positions. Abivax is considered cheap at $0.28 compared to $5.04, but would need a 32.6733% drop. The financial update is not the same as a clinical binary event. MillerKnoll's prior minimum of 52 is greater than 30, but neither provides a live entry. On Monday, fresh quotes from SFIX and BB remain actionable, and on Tuesday, the actual MLKN and survey outcomes will be recorded. Stronger or weaker survey data changes the context but does not create an option edge. Early issuer news or a date change can realign the event and cancel the pending premise. The FDA whole market decision census remains incomplete, and the explicit no-known-live FDA candidate is not proof that none exist. Dates are chosen to review inputs, with no invented announcement hours.

The automated trading fund manager made a final decision to hold 100% cash, explicitly rejecting SFIX, which refers to Stitch Fix, a company that provides online personal shopping services. The decision was based on several premises, including the reverified issuer of SFIX on September 23, with an unchanged ask price of $2.5 on October 16. A news scan found the press release at https://investors.stitchfix.com/news-events/press-releases/news-details/2026/Stitch-Fix-Announces-Date-for-Fourth-Quarter-and-Full-Fiscal-Year-2026-Financial-Results-and-Conference-Call/default.aspx. The manager considered a 21.83% increase in price versus a median of 16.57% and a potential payoff of 1.97 times the investment, but rejected the ticket SFIX261016P00002500 with a $28 premium. The manager also considered other events, including a study on BB, which refers to a stock ticker, with a hurdle rate of 14.89% versus a median of 9.11%, and a potential payoff of 0.17 times the investment. The manager also looked at MLKN, which refers to Miller Knoll, and CAG, which refers to Conagra Brands, but found that the options were too expensive. The conclusion is to retain 100% cash and not place any orders while research is ongoing. The manager will re-evaluate the options on Monday at 9:50 and 12:30 and consider repricing, recomputing net odds, and adjusting the premium and target prices. The manager is watching SFIX and BB, but notes that neither is a quote, and will only hold the position if the price move is less than or equal to the realized median. The research coverage includes four US-listed and Canadian stocks, but is not exhaustive, and the manager notes that there is no edge in the whole market. Existing positions in SFIX and new positions in BB have been preserved, and no new fund proposal has been made.

The automated trading fund manager made a final decision to retain 100% cash. The decision was based on several premises. Firstly, the issuer confirmed the September 23 AMC results on September 2, which is valid. Secondly, the current ask price for the October 16 put option is $2.84, with a premium of $0.28, which is 2.8% of the equity. However, the break-even point is a 21.83% fall, which is higher than the median of 16.58% and the 80th percentile down payoff of 5.52%. The manager rejected both mandate branches. Thirdly, a put option at $0.13 would pass the gross test, but it is not available at the ask price. The best rejected ticket remains SFIX261016P00002500. Fourthly, a call option at $2.5 would cost $53, which is higher than the $30 cap. An out-of-the-money call option at $0.03 would require a 77.11% rise, with an 80th percentile payoff of zero. The manager also considered the cost of a 7-option diagnostic training gain and model volatility sensitivity, but it cannot be claimed as a validated net expectancy. Therefore, the manager chose to retain 100% cash. The market was also closed, which prohibits orders. The manager will monitor the market and may create an affordable probe if the conditions change. The manager will use the entire premium as risk and stop at 50% paid, with a target of 3x paid or defended 80th percentile payoff. The manager will hold through only if the price move is less than or equal to the realized median. If only the tail branch passes but the median fails, the manager will reconcile the pre-event exit rather than secretly changing the hold rule. The manager will not invent false fills or let stubs substitute for meaningful tails. The manager noted that the Friday indicative spread is $0.25, and there are execution gaps due to stale contract metadata. The manager will monitor the outcome on Monday at 09:50 and will collect prices every 240 minutes, with 36 runs passed. The manager will also review the issuer status via the web.